相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis
Vishesh Sarin et al.
LEUKEMIA (2020)
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression
Zachary J. Walker et al.
BLOOD ADVANCES (2020)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft
Ping Chen et al.
ANNALS OF HEMATOLOGY (2018)
Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes
Brett M. Stevens et al.
NATURE COMMUNICATIONS (2018)
Update on the role of lenalidomide in patients with multiple myeloma
Sarah A. Holstein et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma
Salomon Manier et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Upregulation of Far Upstream Element-Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma
Junyao Duan et al.
PLOS ONE (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future
Daniel W. Sherbenou et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
SynergyFinder: a web application for analyzing drug combination dose-response matrix data
Aleksandr Ianevski et al.
BIOINFORMATICS (2017)
AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers
Alexander W. Hird et al.
CANCER RESEARCH (2017)
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1
Jia-Nan Gong et al.
BLOOD (2016)
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells
Daniel W. Sherbenou et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma
Shirong Li et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Final Analysis of the Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic- or Accelerated-Phase Chronic Myeloid Leukemia: Results With 24 Months of Follow-Up
Jorge E. Cortes et al.
CANCER (2015)
Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E
Victoria Zismanov et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Homoharringtonine and omacetaxine for myeloid hematological malignancies
Shuqing Lu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
M. Affer et al.
LEUKEMIA (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
John Nemunaitis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
BH3 profiling - Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions
Victoria Del Gaizo Moore et al.
CANCER LETTERS (2013)
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Jorge Cortes et al.
BLOOD (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia
Rong Chen et al.
BLOOD (2011)
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
Antonia Lopez-Girona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma
W-J Chng et al.
LEUKEMIA (2011)
Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells
E. K. Allan et al.
LEUKEMIA (2011)
Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma
Jana Balcarkova et al.
CANCER GENETICS AND CYTOGENETICS (2009)
U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics: The Structures of Tiamulin, Homoharringtonine, and Bruceantin Bound to the Ribosome
Gueliz Guerel et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
Universal sample preparation method for proteome analysis
Jacek R. Wisniewski et al.
NATURE METHODS (2009)
Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin
Junya Kuroda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Haitao Meng et al.
LEUKEMIA & LYMPHOMA (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Refractory multiple myeloma treated with homoharringtonine: report of two cases
Xiudi Yang et al.
ANNALS OF HEMATOLOGY (2007)
Homoharringtonine induces apoptosis and growth arrest in human myeloma cells
Yin-Jun Lou et al.
LEUKEMIA & LYMPHOMA (2007)
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Ichiro Hanamura et al.
BLOOD (2006)
Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
RP Tang et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
S Wuillème-Toumi et al.
LEUKEMIA (2005)
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
H Avet-Loiseau et al.
BLOOD (2001)
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
YP Shou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
